Hikma Pharmaceuticals (LON:HIK) Interview Extract
You're announcing strong first half results today. What's driven that performance?
I have to say I'm very, very happy, we're extremely pleased by the results that we announced today. We're looking at revenues up by 11.3%, we're looking at our operating profits up by 20%, gross margins are almost 50%, fantastic cash flow growth by 74%, and we have a fantastic net debt to equity ratio of 18%. So we're very, very happy with these numbers. I've always said that this is a very well diversified business, and we have three main engines that continuously feed this growth. So this year for the first half, the US Generic business did extremely, extremely well, so we're very happy with that. That has been fantastic growth. Our Injectable business for the first half was very good also, we're very happy with that. And the Brand business, as we had previously said, would this year be split almost evenly between the first half and second half. So the Brand business was stable and we are looking at very good growth in the Brand business for the second half of the year. So overall, all three engines have been performing quite well, and the diversity and diversification has come in and worked again to give us these fantastic results....
